SG Americas Securities LLC Makes New Investment in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 55,004 shares of the company’s stock, valued at approximately $37,000.

Several other hedge funds also recently modified their holdings of the stock. Ensign Peak Advisors Inc boosted its position in X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares during the last quarter. K2 Principal Fund L.P. bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $284,000. Bank of New York Mellon Corp boosted its holdings in shares of X4 Pharmaceuticals by 39.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after buying an additional 133,398 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after buying an additional 388,115 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after buying an additional 23,831 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $0.50 on Wednesday. The firm’s fifty day moving average price is $0.63 and its two-hundred day moving average price is $0.80. X4 Pharmaceuticals, Inc. has a 1 year low of $0.47 and a 1 year high of $1.60. The firm has a market capitalization of $83.55 million, a P/E ratio of -0.71 and a beta of 0.36. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million during the quarter. As a group, research analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at $581,742.15. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the transaction, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock worth $321,447 over the last 90 days. Company insiders own 1.08% of the company’s stock.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.